Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Lilly Endowment Inc., a reporting person for Eli Lilly and Company (LLY), reported multiple open‑market sales of common stock on 11/05/2025, totaling 40,432 shares across eight transactions coded “S.”
The trades executed at weighted‑average prices with ranges disclosed from $947.18 to $955.41. Following these transactions, the reporting person beneficially owned 93,711,978 shares with direct ownership.
Lilly Endowment Inc., a reporting person for Eli Lilly and Company (LLY), reported multiple open‑market sales of common stock on 11/05/2025, totaling 40,432 shares across eight transactions coded “S.”
The trades executed at weighted‑average prices with ranges disclosed from $947.18 to $955.41. Following these transactions, the reporting person beneficially owned 93,711,978 shares with direct ownership.
Lilly Endowment Inc., a reporting person for Eli Lilly and Company (LLY), reported multiple open‑market sales of common stock on 11/05/2025, totaling 40,432 shares across eight transactions coded “S.”
The trades executed at weighted‑average prices with ranges disclosed from $947.18 to $955.41. Following these transactions, the reporting person beneficially owned 93,711,978 shares with direct ownership.
Eli Lilly & Co (LLY): A reporting person identified as a director and 10% owner reported open‑market sales of common stock on 11/05/2025 across 30 separate transactions. The trades were executed at weighted‑average prices disclosed by tranche, with individual price ranges noted in the footnotes.
Following these sales, the reporting person directly beneficially owned 93,752,410 shares. The footnotes show sale price ranges spanning from $910.90 to $947.06 per share across the listed tranches. The remark states this is the first of two Forms 4 filed the same day, covering transactions #1–#30 of 38 total.
Eli Lilly & Co (LLY): A reporting person identified as a director and 10% owner reported open‑market sales of common stock on 11/05/2025 across 30 separate transactions. The trades were executed at weighted‑average prices disclosed by tranche, with individual price ranges noted in the footnotes.
Following these sales, the reporting person directly beneficially owned 93,752,410 shares. The footnotes show sale price ranges spanning from $910.90 to $947.06 per share across the listed tranches. The remark states this is the first of two Forms 4 filed the same day, covering transactions #1–#30 of 38 total.
Eli Lilly & Co (LLY): A reporting person identified as a director and 10% owner reported open‑market sales of common stock on 11/05/2025 across 30 separate transactions. The trades were executed at weighted‑average prices disclosed by tranche, with individual price ranges noted in the footnotes.
Following these sales, the reporting person directly beneficially owned 93,752,410 shares. The footnotes show sale price ranges spanning from $910.90 to $947.06 per share across the listed tranches. The remark states this is the first of two Forms 4 filed the same day, covering transactions #1–#30 of 38 total.
Lilly Endowment Inc., a director of Eli Lilly (LLY), reported selling 526 shares of common stock on 11/04/2025 with transaction code S. The sale was executed at a weighted average price of $910.719.
The shares were sold in multiple trades at prices ranging from $910.59 to $911.00. After this transaction, the reporting person beneficially owned 93,931,452 shares, held directly.
Lilly Endowment Inc., a director of Eli Lilly (LLY), reported open‑market sales totaling 300,000 shares of common stock on 11/03/2025.
The trades were executed in multiple tranches at weighted average prices with reported ranges from $877.00 to $901.295 per share, as detailed in footnotes. Following these transactions, the reporting person beneficially owned 93,931,978 shares directly.
Lilly Endowment Inc. filed a Form 144 notice to sell up to 220,000 shares of Eli Lilly and Company (LLY) common stock, reflecting an aggregate market value of $197,236,600. The filing lists J.P. Morgan Securities LLC as broker and an approximate sale date of 11/04/2025.
Shares outstanding were 945,383,757. The Endowment reports prior sales in the last three months, including 351,015 shares on 10/01/2025 for $284,653,451.48 and 300,000 shares on 11/03/2025 for $266,648,940. The securities trace back to a historical gift acquisition from the J.K. Lilly Sr. Trust.
Eli Lilly (LLY): insider transaction reported. On 10/31/2025, the reporting person executed open-market sales of common stock across multiple tranches totaling 301,342 shares. The weighted average prices for each tranche reflected ranges from $862.00 to $869.9057, as disclosed in footnotes. Following these transactions, the reporting person beneficially owned 94,231,978 shares, held directly.
The sales were recorded as code “S” and reported with weighted average prices for each tranche; detailed per-trade pricing within the stated ranges is available upon request, according to the disclosure. The filing was signed “/s/ Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.”
Lilly Endowment Inc. filed a Form 144 notice to sell 300,000 shares of Eli Lilly and Company common stock. The filing lists an aggregate market value of $258,858,000, with Fidelity Capital Markets as broker and an approximate sale date of 11/03/2025. The shares are listed on NYSE and NASDAQ.
Shares outstanding were 945,383,757; this is a baseline figure, not the amount being offered. In the past three months, the seller reported multiple open-market sales, including 351,015 shares on 10/01/2025 for $284,653,451.48 and 301,342 shares on 10/31/2025 for $260,164,971.74.
Lilly Endowment, Inc. filed Amendment No. 43 to Schedule 13G reporting beneficial ownership of 95,492,993 shares of Eli Lilly (LLY) common stock, representing 10.1% of the class. The ownership is reported as of September 30, 2025, and the percentage is based on 946,456,759 shares outstanding as of August 4, 2025 per the issuer’s Form 10‑Q.
The Endowment has sole voting power and sole dispositive power over 95,492,993 shares, with no shared voting or dispositive power. The filer is an Indiana not‑for‑profit organization and private foundation.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of Eli Lilly (LLY) common stock. As of 09/30/2025, Vanguard reported 80,952,595 shares, representing 8.55% of the class. Vanguard is identified as an investment adviser and certified the holdings were acquired and are held in the ordinary course, not to change or influence control.
The filing details 0 shares with sole voting power and 4,843,238 shares with shared voting power. Vanguard reported 73,223,987 shares with sole dispositive power and 7,728,608 shares with shared dispositive power. The filing also notes that Vanguard’s clients have rights to dividends or sale proceeds, and no single other person’s interest exceeds 5%.
Eli Lilly (LLY) reported sharply higher Q3 results. Revenue rose to $17,600.8 million from $11,439.1 million a year ago, driven by cardiometabolic medicines. Net income increased to $5,582.5 million from $970.3 million, with diluted EPS of $6.21 versus $1.07.
Growth was led by Mounjaro ($6,515.1 million total) and Zepbound ($3,588.1 million), lifting total cardiometabolic health revenue to $13,177.9 million. Oncology contributed $2,407.6 million, and immunology $1,362.4 million. Operating cash flow for the nine months reached $13,588.4 million. Cash and equivalents were $9,791.9 million, while long‑term debt was $40,873.6 million. The company recognized $655.7 million of acquired IPR&D and $364.9 million of special charges in the quarter.
Lilly completed the Verve Therapeutics acquisition for $549.4 million net of cash, with a contingent value right of up to $300.0 million. Pre‑launch inventories were $952.3 million, primarily for orforglipron. As of September 30, $12.40 billion remained under the $15.00 billion share repurchase authorization. Shares outstanding were 945,383,757 as of October 27, 2025.